SCLXW (Scilex Holding Company Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by SCLXW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-20 | Stephen Hoi Ma | CFO, COO and Secretary | Buy | — | — |
| 2026-04-20 | Henry Ji | Exec Chair, CEO and President | MIXED | — | — |
| 2025-12-30 | Scilex Holding Co | 10%+ Owner | Sell | — | — |
| 2025-10-09 | Stephen Hoi Ma | CFO and COO | A | — | — |
| 2025-10-09 | Yue Alexander Wu | Director | A | — | — |
| 2025-10-09 | Jay Chun | Director | A | — | — |
| 2025-10-09 | Dorman Followwill | Director | A | — | — |
| 2025-10-09 | Henry Ji | CEO and President | A | — | — |
| 2025-01-23 | SCLX Stock Acquisition JV LLC | 10%+ Owner | J | — | — |
| 2025-01-17 | SCLX Stock Acquisition JV LLC | 10%+ Owner | J | — | — |
| 2025-01-06 | SCLX Stock Acquisition JV LLC | 10%+ Owner | J | — | — |
| 2024-12-18 | JAISIM SHAH | See Remarks | Buy | — | — |
| 2024-12-17 | Dorman Followwill | Director | A | — | — |
| 2024-12-17 | Yue Alexander Wu | Director | A | — | — |
| 2024-12-17 | Jay Chun | Director | A | — | — |
| 2024-10-31 | Henry Ji | Executive Chairperson | Buy | — | — |
| 2024-10-29 | JAISIM SHAH | See Remarks | Buy | — | — |
| 2024-10-18 | Jay Chun | Director | Buy | — | — |
| 2024-10-18 | David Lemus | Director | Buy | — | — |
| 2024-10-18 | Yue Alexander Wu | Director | Buy | — | — |
| 2024-10-18 | Henry Ji | Executive Chairperson | Buy | — | — |
| 2024-10-18 | Dorman Followwill | Director | Buy | — | — |
| 2024-10-17 | JAISIM SHAH | See Remarks | Buy | — | — |
| 2024-10-17 | Stephen Hoi Ma | Chief Financial Officer | Buy | — | — |
| 2024-08-19 | Annu Navani | Director | A | — | — |
| 2024-06-26 | Dorman Followwill | Director | A | — | — |
| 2024-06-26 | Dorman Followwill | Director | M | — | — |
| 2024-06-26 | David Lemus | Director | A | — | — |
| 2024-06-20 | Jay Chun | Director | M | — | — |
| 2024-06-20 | Stephen Hoi Ma | Chief Financial Officer | M | — | — |
| 2024-06-20 | JAISIM SHAH | See Remarks | M | — | — |
| 2024-06-20 | Yue Alexander Wu | Director | M | — | — |
| 2024-06-18 | Henry Ji | Executive Chairperson | M | — | — |
| 2024-06-14 | JAISIM SHAH | See Remarks | M | — | — |
| 2024-05-17 | JAISIM SHAH | See Remarks | Buy | — | — |
| 2024-05-17 | Stephen Hoi Ma | Chief Financial Officer | Buy | — | — |
| 2024-05-17 | Henry Ji | Executive Chairperson | Buy | — | — |
| 2024-05-17 | Jay Chun | Director | Buy | — | — |
| 2023-10-05 | Stephen Hoi Ma | Chief Financial Officer | A | — | — |
| 2023-10-05 | Yue Alexander Wu | Director | A | — | — |
| 2023-10-05 | JAISIM SHAH | See Remarks | A | — | — |
| 2023-10-05 | Henry Ji | Executive Chairperson | A | — | — |
| 2023-10-05 | Jay Chun | Director | A | — | — |
| 2023-09-25 | Sorrento Therapeutics, Inc. | 10%+ Owner | Sell | — | — |
| 2023-03-20 | Henry Ji | Executive Chairperson | J | — | — |
| 2023-01-23 | Sorrento Therapeutics, Inc. | 10%+ Owner | J | — | — |
| 2023-01-17 | JAISIM SHAH | See Remarks | A | — | — |
| 2023-01-17 | Laura Hamill | Director | A | — | — |
| 2023-01-17 | Tien-Li Lee | Director | A | — | — |
| 2023-01-17 | David Lemus | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 261,413,544 | — |
| — | 10%+ Owner | 51,039,214 | — |
| — | 10%+ Owner | 1,917,210 | — |
| — | Exec Chair, CEO and President | 322,910 | — |
| — | See Remarks | 295,215 | — |
| — | Director | 112,511 | — |
| — | Director | 25,000 | — |
| — | CFO, COO and Secretary | 22,840 | — |
| — | Director | 2,300 | — |
| — | Director | 2,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SCLXW quote page; the site-wide leaderboard is on the insider transactions hub.